# unlearn.ai: Research, San Francisco, United States > unlearn.ai: Unlearn.AI is a technology company founded in 2017 and based in San Francisco, California, with an additional office in Cambridge, Massachusetts. Source: https://millionrounds.com/startup/unlearn-ai (Millionrounds; every figure on the page links to its filing or article) United States · [Research startup](https://millionrounds.com/companies) # unlearn.ai Unlearn.AI is a technology company founded in 2017 and based in San Francisco, California, with an additional office in Cambridge, Massachusetts. Email Funding reported Last round: Series C Research San Francisco, United States Follow unlearn.ai and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Funlearn-ai) Company summary - **Founded:** 2017 9 years old - **Team:** 75 51 to 200 people - **Funding reported:** $135M in dollars - **Last round:** Series C Feb 2024 How sure we are - ✓ **Listed** We know it exists and what it does - 2 **Funding reported** A company dataset reports a raise - 3 **Observed** A filing or a dated announcement confirms a round No round for unlearn.ai has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology) ## About unlearn.ai Unlearn.AI is a technology company founded in 2017 and based in San Francisco, California, with an additional office in Cambridge, Massachusetts. The company specializes in the intersection of artificial intelligence, biostatistics, and clinical research, focusing on the development of digital twins to enhance clinical trials. Unlearn.AI aims to make clinical trials smarter, faster, and more efficient by eliminating traditional trial and error methods in medicine. The company offers AI-powered digital twins that serve as statistical forecasts for clinical trial participants, replacing traditional placebo groups. Its key products include TwinRCTTM, a suite of statistical methods that enables smaller, more efficient trials, and PROCOVATM, a patent-pending method that adjusts for prognostic covariates to optimize sample sizes. Unlearn.AI's technology helps pharmaceutical and biotech companies reduce trial timelines, lower costs, and address ethical concerns related to placebo use, ultimately accelerating the delivery of life-saving treatments. ## What company datasets say unlearn.ai raised Funding, as reported Reported in all **$135M** in dollars Rounds **7** Last round **Series C** Last round size **$50M** Last round date **Feb 2024** Investors listed **15** SEC Form D **$127M sold, 4 filings, last Feb 2024** ## Founders and team From unlearn.ai's own website and the SEC filings it signed: 2 founders, 6 on the team. **Jon Walsh** Founder & Chief Scientific Officer **Aaron Smith** Founder & Head of AI *Named on its 2024 Form D* - **Steve Herne** Chief Executive Officer - **Andrew Stelzer** Chief Commercial Officer - **Prathyusha Duraibabu** Chief Financial & Operating Officer - **Andrew Gill** Executive Officer i - **Charles Fisher** Executive Officer, Director i - **John McGovern** Executive Officer i On the board, as filed i *Ann Taylor* *Eric Shiozaki* *Ermira Murati* ## On 3 portfolio pages Investors who name them - [8VC](https://millionrounds.com/fund/8vc) - [Eisai Innovation](https://millionrounds.com/fund/eisai-innovation) - [Flucas Ventures](https://millionrounds.com/fund/flucas-ventures) Each firm lists unlearn.ai on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source. ## The company, in detail What they build Known for health care ai for clinical data integration cross-functional collaboration ai in neurodegenerative diseases clinical trial predictive tools clinical trial success optimization ai for trial design in neurology patient outcome prediction ai in rare diseases ai-driven trial design data science single-arm studies enterprises ai for safety signal detection ai for placebo control reduction medical research Built with from their website Amazon SES Google Tag Manager Amazon CloudFront WordPress.org Atlassian YouTube MailChimp Google Workspace CloudFlare Viewport Meta +8 more Google Drive Amazon Simple Email Service Hubspot Webflow Hosting AI Google Meet NetSuite CloudFlare CDN - **Sector:** Research - **Industry code:** NAICS 54171, 51321, SIC 8731, 7372 - **Region:** California - **Revenue:** $5.4M a year, as listed - **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/unlearn-ai) ## Research in United States Startups like it - [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai) - [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences) - [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit) - [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos) - [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences) - [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic) - [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines) - [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences) ## Is this your company? Add your raise, your deck and your story, and put unlearn.ai in front of investors. Or tell us what we have wrong. [List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)